Drawing for ADIPEX-P

USPTO serial 73078717

ADIPEX-P

Reviewed by CopyMark Law Group

Reg. 1063091Status 703Renewal
Filing date
Status date
Registration date
Apr 12, 1977
Examiner
—
Law office
GENERIC WEB UPDATE

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 703: Status 703 means Section 8 was accepted and a Section 15 incontestability declaration is pending USPTO review. The registration remains active while Section 15 is processed.

Need help with ADIPEX-P?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*

Plus Government fees of $650

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Herschel Perel

Herschel Perel Teva Pharmaceuticals USA, Inc.425 Privet RoadTrademarks DepartmentHorsham, PA 19044

Goods and services

ClassDescriptionStatusFirst use
005ANTI-OBESITY PREPARATIONACTIVEJan 29, 1976

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 12, 2026REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Mar 23, 2017NA89NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED—
Mar 23, 2017NA15SEC. 15 ACKNOWLEDGEMENT - E-MAILED—
Mar 23, 201715AKREGISTERED - SEC. 15 ACKNOWLEDGED—
Mar 23, 2017RNL3REGISTERED AND RENEWED (THIRD RENEWAL - 10 YRS)The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active.
Mar 23, 201789AGREGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTEDThe USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary.
Mar 20, 2017E89RTEAS SECTION 8 & 9 RECEIVED—
Mar 20, 2017E15RTEAS SECTION 15 RECEIVED—
Mar 20, 2017TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 20, 2017TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 12, 2016REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Jul 3, 2008RNL2REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active.
Jul 3, 200889AGREGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTEDThe USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary.
Nov 13, 2007CFITCASE FILE IN TICRS—
Aug 1, 200789AFREGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED—
Aug 1, 2007E89RTEAS SECTION 8 & 9 RECEIVED—
May 5, 2007XXXXPOST REGISTRATION ACTION CORRECTION—
Apr 4, 200789AFREGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED—
Apr 4, 2007E89RTEAS SECTION 8 & 9 RECEIVED—
Feb 3, 1998RNL1REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active.
Nov 10, 1997RRPRRESPONSE RECEIVED TO POST REG. ACTION—
May 6, 1997PRA9POST REGISTRATION ACTION MAILED - SEC. 9—
Apr 7, 19979.AFREGISTERED - SEC. 9 FILED/CHECK RECORD FOR SEC. 8—
Jul 26, 1982C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—

Frequently asked questions

Related guidance